Compare IQV & AMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | AMP |
|---|---|---|
| Founded | 1982 | 1894 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 42.4B |
| IPO Year | 2013 | 2008 |
| Metric | IQV | AMP |
|---|---|---|
| Price | $164.74 | $442.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | $230.56 | ★ $560.20 |
| AVG Volume (30 Days) | ★ 2.4M | 596.9K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.45% |
| EPS Growth | 4.67 | ★ 9.77 |
| EPS | 7.84 | ★ 36.28 |
| Revenue | $9,739,000,000.00 | ★ $18,911,000,000.00 |
| Revenue This Year | $6.76 | $1.71 |
| Revenue Next Year | $5.85 | $4.38 |
| P/E Ratio | $20.74 | ★ $12.13 |
| Revenue Growth | ★ 41.60 | 5.49 |
| 52 Week Low | $134.65 | $396.14 |
| 52 Week High | $247.05 | $550.18 |
| Indicator | IQV | AMP |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 34.85 |
| Support Level | $156.43 | N/A |
| Resistance Level | $166.38 | $515.17 |
| Average True Range (ATR) | 6.33 | 11.60 |
| MACD | 1.34 | -2.31 |
| Stochastic Oscillator | 20.98 | 5.01 |
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating income from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third key segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.